B
BioCryst Pharmaceuticals, Inc.
BCRX · NASDAQ · Healthcare · 2.5B
Closing price
$8.55
+3.14% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
6.8×
Price / net assetsP/B
—
Enterprise value / EBITDAEV/EBITDA
6.2×
Free cash flow yieldFCF yield
18.2%
Return on equityROE
-221.4%
Operating margin
39.0%
Net debt / EBITDAbalance-sheet strength
1.0×
Interest coverage
4.3×
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.